Augmentin Tab 1g (HK-42252) and Augmentin Tab 625mg (HK-44027) (collectively, "Products")

Augmentin Tab 1g (HK-42252) and Augmentin Tab 625mg (HK-44027) (collectively, "Products")
(3 August, 2011 - Hong Kong) Today, GlaxoSmithKline Limited ("GSK") announces a retail level recall of the Products from the Hong Kong market due to the presence of trace levels of phthalates found during GSK internal testing.

Phthalates are ubiquitous and present as trace compounds in the environment and in many common items of daily consumption.  The levels of phthalates detected in the Products during tests commissioned by GSK remain significantly lower than the levels that the USA and European authorities deem as presenting no level of risk to humans.  In many of the batches tested results were below the limit of quantification of the method (1ppm).  Results of these tests were submitted to the Hong Kong Department of Health's ("DH") assessment on 2 August 2011, whilst GSK continues its investigation in determination of the potential source(s) of phthalates in the manufacturing process of the Products.  We can confirm that GSK does not intentionally use any phthalates of any Augmentin products.

For enquiries, please call our hotline 3189 8765 within the office hour (9am - 5:30pm on Monday to Friday).

About Augmentin Tablet
Augmentin Tablet is an antibiotic and according to DH's announcement, patients who are currently using this product for treatment should consult their attending doctors or pharmacists as soon as possible and not to just stop using the drug.

About GlaxoSmithKline
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit us at www.gsk.com.

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.